Sign in
Taking people in United StatesPhase 2

Sodium Thiosulfate Injection for Calcium Deposits in Connective Tissue Diseases

Tests sodium thiosulfate injected into calcium deposits in adults with scleroderma or related diseases.

Key facts

Who runs it
Robyn T. Domsic, MD, MPH
Where
Pittsburgh, United StatesSee the site
Trial code
Registry title
Intralesional Injection of STS in Treatment of Calcinosis
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
17 Mar 2025
Expected to end
1 May 2029
Type of study
Interventional
Treatments tested
  • Sodium Thiosulfate (STS)
Record updated
5 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with systemic sclerosis, mixed connective tissue disease or inflammatory myopathy who have calcium deposits (calcinosis) and need symptom relief.

Age
Over 18 years
Sex
All sexes can join
Disease stage
A clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy. Calcinosis must show on an x-ray or ultrasound.

Main reasons for not taking part

  • Pregnant women cannot join

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy
  • Must be over 18 years of age
  • Participants must be competent to give informed consent
  • Participants must have radiographic evidence (xray or ultrasound) of calcinosis
  • Participants must need symptomatic relief

Who cannot take part

  • Pregnant women will be excluded

Where in United States

  • UPMC Arthritis and Autoimmunity CenterPittsburgh, United StatesContact: Office ManagerTaking people

About the trial

What the trial wants to find out

The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.

The group in the trial

  • Sodium thiosulfate (STS)Treatment being tested

    Open label, single-arm, receiving 1-5ml of STS (250mg/ml) sodium thiosulfate (STS) injections to calcinosis lesions.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open Label Evaluation of Intralesional Injection of Sodium Thiosulfate in the Treatment of Cutaneous or Tendon Calcinosis in Connective Tissue Disease
Plain-language title
Sodium Thiosulfate Injection for Calcium Deposits in Connective Tissue DiseasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 May 2026